Notably, our findings also revealed significant anti-MM effects of a newly developed SRC-3 inhibitor, SI-2, with BTZ, and shed light on developing strategies using SI-2 to overcome drug resistance in MM patients. This evidence concerns the gene NCOA3 and Miyoshi myopathy.